Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247796 | 0.81 | CA2 (0.55) | FFAR1CA2 | |
| SCHEMBL4247794 | 0.81 | CA2 (0.55) | FFAR1CA2 | |
| SCHEMBL6979181 | 0.79 | CA2 (0.47) | FFAR1CA2PYGLHTR6MAPK1 | |
| SCHEMBL1883283 | 0.79 | CA2 (0.47) | FFAR1CA2PYGLHTR6MAPK1 | |
| SCHEMBL15870267 | 0.78 | FFAR1 (0.41) | FFAR1CA2PYGLHTR6MAPK1 | |
| SCHEMBL17272748 | 0.78 | FFAR1 (0.41) | FFAR1CA2PYGLHTR6MAPK1 | |
| SCHEMBL17272320 | 0.77 | CA2 (0.33) | FFAR1CA2HTR6L3MBTL1MAPK1 | |
| SCHEMBL15865430 | 0.76 | CA2 (0.47) | FFAR1CA2HTR6L3MBTL1MAPK1 | |
| SCHEMBL17272718 | 0.76 | CA2 (0.47) | FFAR1CA2HTR6L3MBTL1MAPK1 | |
| SCHEMBL13450820 | 0.76 | FFAR1 (0.50) | FFAR1CA2PYGLHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745382-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3362443-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066227-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745382-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | FFAR1 3749/4885CA2 4677/4885PYGL 1258/4885 |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | FFAR1 3749/4885CA2 4677/4885PYGL 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.